New insights into chronic inducible urticaria.

IF 5.4 2区医学 Q1 ALLERGY Current Allergy and Asthma Reports Pub Date : 2024-08-01 Epub Date: 2024-07-19 DOI:10.1007/s11882-024-01160-y

Melba Muñoz, Lea Alice Kiefer, Manuel P Pereira, Mojca Bizjak, Marcus Maurer

{"title":"New insights into chronic inducible urticaria.","authors":"Melba Muñoz, Lea Alice Kiefer, Manuel P Pereira, Mojca Bizjak, Marcus Maurer","doi":"10.1007/s11882-024-01160-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: Chronic inducible urticaria (CIndU) is a group of long-persisting and challenging to manage diseases, characterized by recurrent wheals and angioedema induced by definite triggers. In this review, we address recent findings on CIndU pathogenesis, diagnosis as well as its treatment, and we discuss novel potential targets that may lead to the development of more effective therapies for CIndU patients.Recent advances: Meaningful advances in the understanding of its pathogenesis have been reported in the last decades. Novel CIndU-specific patient-reported outcome measures enable a closer and better evaluation of patients. CIndU is a hard-to-treat disease that highly impairs quality of life (QoL) of affected patients. Provocation tests allow to diagnose CIndU subtypes. The only licensed and recommended treatment for CIndU are second generation non-sedating H1-antihistamines, which lack efficacy in many cases. Omalizumab off-label use has been assessed in all types of CIndU with overall good outcomes. Promising emerging therapies currently assessed in chronic spontaneous urticaria are paving the path for novel treatments for CIndU.","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"457-469"},"PeriodicalIF":5.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297124/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Allergy and Asthma Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11882-024-01160-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Chronic inducible urticaria (CIndU) is a group of long-persisting and challenging to manage diseases, characterized by recurrent wheals and angioedema induced by definite triggers. In this review, we address recent findings on CIndU pathogenesis, diagnosis as well as its treatment, and we discuss novel potential targets that may lead to the development of more effective therapies for CIndU patients.

Recent advances: Meaningful advances in the understanding of its pathogenesis have been reported in the last decades. Novel CIndU-specific patient-reported outcome measures enable a closer and better evaluation of patients. CIndU is a hard-to-treat disease that highly impairs quality of life (QoL) of affected patients. Provocation tests allow to diagnose CIndU subtypes. The only licensed and recommended treatment for CIndU are second generation non-sedating H1-antihistamines, which lack efficacy in many cases. Omalizumab off-label use has been assessed in all types of CIndU with overall good outcomes. Promising emerging therapies currently assessed in chronic spontaneous urticaria are paving the path for novel treatments for CIndU.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对慢性诱发性荨麻疹的新认识。

综述的目的：慢性诱发性荨麻疹（CIndU）是一类长期存在且难以控制的疾病，其特点是由明确的诱发因素诱发反复发作的喘息和血管性水肿。在这篇综述中，我们探讨了有关诱发性荨麻疹发病机制、诊断和治疗的最新发现，并讨论了可能为诱发性荨麻疹患者开发出更有效疗法的潜在新靶点：最近的进展：在过去几十年中，人们对CIndU发病机制的认识取得了重大进展。新的CIndU特异性患者报告结果测量方法使我们能够更仔细、更好地评估患者。CIndU是一种难以治疗的疾病，严重影响患者的生活质量（QoL）。激发试验可以诊断 CIndU 亚型。CIndU的唯一许可和推荐治疗药物是第二代非镇静型H1-抗组胺药，但在许多病例中缺乏疗效。奥马珠单抗已被评估用于所有类型的CIndU，总体疗效良好。目前在慢性自发性荨麻疹中评估的新兴疗法前景广阔，为CIndU的新型疗法铺平了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Allergy and Asthma Reports 医学-过敏

CiteScore

11.20

自引率

1.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of Current Allergy and Asthma Reports is to systematically provide the views of highly selected experts on current advances in the fields of allergy and asthma and highlight the most important papers recently published. All reviews are intended to facilitate the understanding of new advances in science for better diagnosis, treatment, and prevention of allergy and asthma. We accomplish this aim by appointing international experts in major subject areas across the discipline to review select topics emphasizing recent developments and highlighting important new papers and emerging concepts. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Over a one- to two-year period, readers are updated on all the major advances in allergy and asthma.

期刊最新文献

Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis. Hypersensitivity Reactions to Anticonvulsants. The Impact of the Indoor Environment on Childhood Asthma. Parosmia: Pathophysiology and Management. Effects of Food Processing on Allergenicity.